CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma

计划入组 18 人 · 首次发布于 2026 年 2 月 3 日

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

计划入组 36 人 · 首次发布于 2025 年 6 月 15 日

CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas

计划入组 36 人 · 首次发布于 2025 年 4 月 13 日

dual anti-CD19/anti-BAFF-R CAR T-cell therapy ( Beckman Research Institute )

CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology)

Autologous CAR-T cell therapy expressing the BAFF-ligand

Cell Therapy Ltd.

United Kingdom

Juventas Cell Therapy Ltd

China

T R B PHARMA S.A.

Argentina

PeproMene Bio Secures $11 Million Investment to Advance BAFF-R CAR T-Cell Therapy for Follicular Lymphoma

PeproMene Bio's BAFF-R CAR T-Cell Therapy Shows 80% Complete Response Rate in Relapsed/Refractory B-Cell Lymphomas

Novel BAFF-R CAR-T Therapy Achieves Complete Response in Heavily Pretreated Follicular Lymphoma Patient